Last reviewed · How we verify
NCT06171230: EMDR4CPDN
Eye Movement Desensitization and Reprocessing (EMDR) as a Treatment for Chronic Painful Diabetic Peripheral Neuropathy
NA trial testing Eye Movement Desensitization and Reprocessing in Neuropathic Pain in 10 participants. Status unknown.
31 March 2025
Quick facts
| Lead sponsor | Dijklander Ziekenhuis |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 March 2024 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Eye Movement Desensitization and Reprocessing
- Attention control phase
Conditions studied
- Neuropathic Pain — all drugs for Neuropathic Pain →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
Sponsor
Dijklander Ziekenhuis — full company profile →
Who can join
18 and older, any sex, with Neuropathic Pain or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to investigate the effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) therapy in reducing pain intensity in individuals with chronic painful diabetic neuropathy (PDN). The main questions it aims to answer are: 1. Does EMDR therapy significantly reduce pain intensity in individuals with chronic PDN? 2. What is the impact of EMDR therapy on secondary outcomes, specifically anxiety, sleep disturbances, and personalized pain-related limitations? Additionally, the study will explore the correlation between pain scores and symptoms of post-traumatic stress disorder (PTSD) in individuals with chronic PDN. Participants will undergo EMDR therapy sessions, focusing on the processing of emotionally charged pain-related events and addressing the pain itself. Main tasks for participants include active engagement in EMDR therapy sessions. Treatment outcomes, including changes in pain intensity, anxiety levels, sleep quality, and personalized pain-related limitations, will be monitored throughout the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06171230
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eye Movement Desensitization and Reprocessing
Trials testing the same drug.
- NCT04472988 — Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults · NA · completed
- NCT05836181 — The Effect of Eye Movement Desensitization and Reprocessing Intervention in Hypertension Patient. · NA · completed
Other recruiting trials for Neuropathic Pain
Currently open trials in the same condition.
- NCT07493213 — USG-Guided Shoulder Injections in Frozen Shoulder · NA · recruiting
- NCT07493226 — Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis · NA · recruiting
- NCT06398847 — Virtual Reality (VR) Self-Hypnosis Software · NA · recruiting
- NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
- NCT07436806 — SPS Block vs. Surgical Intercostal Block for Chronic Pain After Thoracoscopic Surgery · NA · recruiting
Other Dijklander Ziekenhuis trials
Trials by the same sponsor.
- NCT06094660 — RFA or Chemical Neurolysis of the Genicular Nerves Compared to Conservative Treatment for Knee Pain Caused by OA · NA · recruiting
- NCT05337202 — the Dutch-GERAF Study · active not recruiting
- NCT04061798 — ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair. · Phase 4 · terminated
- NCT03426293 — Measuring the ACT During Non-cardiac Arterial Procedures. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06171230 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dijklander Ziekenhuis
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06171230.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing